Prospective, randomized, open-label, clinical trial comparing standard and intensive LDL-lowering therapies using rosuvastatin on progression of atherosclerotic plaques, endothelial function, markers for anti-inflammatory properties/obesity/antioxidative properties.
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Atherosclerosis; Hypercholesterolaemia
- Focus Biomarker; Pharmacodynamics
- 07 Feb 2013 Results presented at the 38th International Stroke Conference.
- 30 Nov 2012 Status changed from active, no longer recruiting to completed.
- 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.